Agreement covers therapeutic antibody to treat melanoma.

Morphotek okayed an agreement with CMC Biopharmaceuticals for GMP manufacturing and regulatory documentation support of MORAb-028, a therapeutic antibody targeting advanced melanoma and other cancers.

MORAb-028 is a human IgM mAb that specifically recognizes a cell surface antigen over-expressed on a significant fraction of metastatic melanoma, brain cancers, and non-small-cell-lung carcinoma, according to Morphotek.

Previous articleSun Takes Over Taro for $454M
Next articleBeckman Coulter Selects SAFC Supply Solutions as Licensing Partner